Skip to main content

Table 1 Patient characteristics of the study cohort

From: One year monitoring of SARS-CoV-2 prevalence in a German cohort of patients with cystic fibrosis

Variable

Frequency

n

%

Gender

  

 Male

71

45.5

 Female

85

54.5

Age (y)

  

 < 18

70

44.9

 ≥ 18

86

55.1

CFTR genotype

  

 F508del/F508del

63

40.4

 F508del/G551D

15

9.6

 F508del/other

61

39.1

 Other/other

17

10.9

CF-related diabetesa

58

37.2

 

Mean ± SD

Median

FEV1pp (n = 136 b)

93.2 ± 27.0

98.0

BMIc

20.0 ± 3.9

20.1

  1. Definition of abbreviations: y, years; CFTR, cystic fibrosis transmembrane conductance regulator; FEV1pp, forced expiratory volume in one second, percent predicted; BMI, body mass index; SD, standard deviation
  2. aGlycosylated hemoglobin ≥ 6.5%, fasting plasma glucose ≥ 7 mmol/L, and/or 2-h oral glucose tolerance test (oGTT) plasma glucose ≥ 11 mmol/L.; bn is specified when data are missing (no measurements in children < 6 y); cweight classification of children according to S2 AGA 10/2015 guideline [6] using gender-specific age percentiles
Back to article page

BMC Pulmonary Medicine

ISSN: 1471-2466

Contact us